Stoke doses first Phase 3 patient, books $168M Biogen revenue, narrows loss to $6.9M
Filed March 16, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 18, 2025 · ~1 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade STOK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 5, 2026 6:08 PM